Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria
French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Dupixent has been approved for CSU in Japan and the United Arab Emirates (UAE) and is also under regulatory review in the European Union based on earlier trial readouts. Outside of Japan and the UAE, ...
Press Release: Dupixent Sbla Accepted For FDA Review For The Treatment Of Chronic Spontaneous Urticaria
Dupixent has been approved for CSU in Japan and the United Arab Emirates (UAE) and is also under regulatory review in the EU based on earlier study readouts. Outside of Japan and the UAE, the safety ...
Campbell names Daniel Poland chief enterprise transformation officer
Soup Company announced the appointment of Daniel L. Poland to the newly created role of Executive Vice President and Chief ...
Worldwide Healthcare Trust PLC - Half-year Report
Worldwide Healthcare Trust PLC - Half-year Report PR Newswire LONDON, United Kingdom, November 15 LONDON STOCK EXCHANGE ANNOUNCEMENTWorldwide Healthcare Trust PLCUnaudited ...